Recordati
As of the edition of 20 October 2026, Recordati runs 8 drugs, 6 of them marketed.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Family history
The records place 2 company names in this family.
Drugs by status
| Status | Count |
|---|---|
| Marketed | 6 |
| Went quiet | 1 |
| Status not established | 1 |
| Total | 8 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Silodosin | none listed | 3 |
| Osilodrostat | Ends 2033 (patent) | 0 |
| Potassium citrate anhydrous | none listed | 0 |
| Lercanidipine | none listed | 0 |
| Sutimlimab | Ends 2034 (computed from the first US licence) | 2 |
| Tilactase | none listed | 0 |
A route B row is one company at one target.